Allergan Korea's Botox Receives Extended Validity Period by KFDA

Allergan Korea announced on March 28th that the Korea Food and Drug Administration (KFDA) approved for an extension of validity period for Botox (botulinum toxin type A) from the existing 2-year period to 3-year period.

According to Allergan Korea, the approval by the KFDA is reflective of the company's proprietary product packaging effort that allows for the extended storage and use of Boto...